By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Progenics Pharmaceuticals, Inc. 

777 Old Saw Mill River Road

Tarrytown  New York  10591  U.S.A.
Phone: 914-789-2800 Fax: 914-789-2817


Progenics Pharmaceuticals, Inc., of Tarrytown, NY is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward symptom management and supportive care and the treatment of HIV infection and cancer. The Company has four product candidates in clinical development and several others in preclinical development.

The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. In the area of HIV infection, the Company is developing the viral-entry inhibitor PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5 (in phase 1b studies). In addition, the Company is conducting research on ProVax, a novel prophylactic HIV vaccine. The Company is developing in vivo immuno-therapies for prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), a protein found on the surface of prostate cancer cells. Progenics is also developing vaccines designed to stimulate an immune response to PSMA. A recombinant PSMA vaccine is in phase 1 clinical testing. The Company is also developing a cancer vaccine, GMK, in phase 3 clinical trials for the treatment of malignant melanoma.

Last Updated: 06-09-2006

Key Statistics

Ownership: Public

Web Site: Progenics Pharmaceuticals, Inc.
Symbol: PGNX

Company News
Progenics Pharmaceuticals, Inc. (PGNX) To Present At 14th Annual Needham Healthcare Conference 4/8/2015 8:19:57 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces The Initiation Of Fuji's Phase 2 Trial For 1404 In Japan 4/7/2015 6:54:16 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces Fourth Quarter And Year-End 2014 Financial Results 3/16/2015 7:54:17 AM
Progenics Pharmaceuticals, Inc. (PGNX) Sets Fourth Quarter And Year End 2014 Financial Results Call For March 16 3/9/2015 8:14:04 AM
Progenics Pharmaceuticals, Inc. (PGNX) Announces Presentation At ENDO 2015 3/3/2015 8:25:25 AM
Progenics Pharmaceuticals, Inc. (PGNX) Presents Positive Phase 2 Data For PSMA ADC In Metastatic Castration-Resistant Prostate Cancer 2/26/2015 10:15:45 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Present Full Phase 2 Data For PSMA ADC At The 2015 American Society of Clinical Oncology GU Symposium 2/24/2015 7:14:32 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Present At The 2015 RBC Capital Markets' Healthcare Conference 2/18/2015 8:11:32 AM
Progenics Pharmaceuticals, Inc. (PGNX) To Present At The 17th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference 2/4/2015 7:47:20 AM
Progenics Pharmaceuticals, Inc. (PGNX) Relaunches Pivotal Trial Of AZEDRA™ In Pheochromocytoma 1/23/2015 7:29:51 AM